Literature DB >> 33688062

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.

Chadi M Saad-Roy1, Sinead E Morris2, C Jessica E Metcalf3,4, Michael J Mina5, Rachel E Baker3,6, Jeremy Farrar7, Edward C Holmes8, Oliver G Pybus9, Andrea L Graham3, Simon A Levin3, Bryan T Grenfell10,4,11, Caroline E Wagner12.   

Abstract

In the face of vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to SARS-CoV-2. Two critical issues arise: how will the timing of delivery of the second dose affect both infection dynamics and prospects for the evolution of viral immune escape via a build-up of partially immune individuals. Both hinge on the robustness of the immune response elicited by a single dose, compared to natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose, and to ramp up vaccination efforts throughout the world.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

Entities:  

Year:  2021        PMID: 33688062     DOI: 10.1126/science.abg8663

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  53 in total

Review 1.  The emergence, genomic diversity and global spread of SARS-CoV-2.

Authors:  Juan Li; Shengjie Lai; George F Gao; Weifeng Shi
Journal:  Nature       Date:  2021-12-08       Impact factor: 49.962

2.  Which vaccination strategy against COVID-19?

Authors:  Alessandro De Matteis; Fethiye B Turkmen Ceylan; Enrico Urpis
Journal:  Int Health       Date:  2022-05-27       Impact factor: 3.131

Review 3.  COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants.

Authors:  Paola Stefanelli; Giovanni Rezza
Journal:  Vaccines (Basel)       Date:  2022-06-06

4.  A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Authors:  Mohammad Reza Rahbar; Shaden M H Mubarak; Anahita Hessami; Bahman Khalesi; Navid Pourzardosht; Saeed Khalili; Kobra Ahmadi Zanoos; Abolfazl Jahangiri
Journal:  Sci Rep       Date:  2022-06-27       Impact factor: 4.996

5.  Unravelling the dynamics of the COVID-19 pandemic with the effect of vaccination, vertical transmission and hospitalization.

Authors:  Rubayyi T Alqahtani; Salihu S Musa; Abdullahi Yusuf
Journal:  Results Phys       Date:  2022-06-14       Impact factor: 4.565

Review 6.  The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic.

Authors:  Sarah P Otto; Troy Day; Julien Arino; Caroline Colijn; Jonathan Dushoff; Michael Li; Samir Mechai; Gary Van Domselaar; Jianhong Wu; David J D Earn; Nicholas H Ogden
Journal:  Curr Biol       Date:  2021-06-23       Impact factor: 10.834

7.  Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 Infection.

Authors:  Taylor F Gunnels; Devin M Stranford; Roxana E Mitrut; Neha P Kamat; Joshua N Leonard
Journal:  Small       Date:  2022-04-07       Impact factor: 15.153

8.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.

Authors:  Mine Durusu Tanriover; Hamdi Levent Doğanay; Murat Akova; Hatice Rahmet Güner; Alpay Azap; Sıla Akhan; Şükran Köse; Fatma Şebnem Erdinç; Emin Halis Akalın; Ömer Fehmi Tabak; Hüsnü Pullukçu; Özgür Batum; Serap Şimşek Yavuz; Özge Turhan; Mustafa Taner Yıldırmak; İftihar Köksal; Yeşim Taşova; Volkan Korten; Gürdal Yılmaz; Mustafa Kemal Çelen; Sedat Altın; İlhami Çelik; Yaşar Bayındır; İlkay Karaoğlan; Aydın Yılmaz; Aykut Özkul; Hazal Gür; Serhat Unal
Journal:  Lancet       Date:  2021-07-08       Impact factor: 79.321

9.  Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.

Authors:  Koen B Pouwels; David W Eyre; A Sarah Walker; Jia Wei; Nicole Stoesser; Philippa C Matthews; Daniel Ayoubkhani; Ruth Studley; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Emma Rourke; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim E A Peto
Journal:  Nat Microbiol       Date:  2021-07-21       Impact factor: 17.745

10.  Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model.

Authors:  Julia R Gog; Edward M Hill; Leon Danon; Robin N Thompson
Journal:  R Soc Open Sci       Date:  2021-07-14       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.